1. Scrip

Syncona Biotechs Face Up To Trial Delays Over COVID-19

Programs Put Back 'At Least Three Months'

 
• By Kevin Grogan

Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.

Delayed
Delays hitting clinical trials across the board • Source: Shutterstock

With the effects of the coronavirus disease spreading across every aspect of health care, UK biotech investment major Syncona has given an update on how COVID-19 is affecting clinical trials at its portfolio companies.

Syncona, founded in 2012 with £250m from the Wellcome Trust, has been fundamental in the founding of a number...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

 
• By Mandy Jackson

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.